It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Home> Safety Information > Guidance for treating physicians

Guidance for treating physicians

Reports from clinicians of events (including intraocular inflammation (IOI), including retinal vasculitis (RV), and of retinal vascular occlusion (RO) that have occurred during marketed use so far in patients with wet AMD suggest that these events can occur as early as the first or second injection of Beovu. Patients reported changes in vision, such as significant increase in floaters or blurry vision, within one to two weeks of treatment.

Before injecting, physicians are encouraged to look for signs of IOI, which may include examination by slit lamp or posterior segment imaging. If active IOI is present, you must not perform an intraocular injection with Beovu and should treat the  IOI according to medical practice. Please instruct your patients to contact you immediately if they notice any changes in visual acuity or any signs of inflammation, such as eye pain, floaters, discomfort or ocular hyperemia.You should discontinue treatment with Beovu in patients who develop adverse events of RV and/or RO.

As a reminder, Beovu is contraindicated in patients with ocular or periocular infections, active intraocular IOI or known hypersensitivity to brolucizumab or any of the excipients. 

The clinical benefits and risks of brolucizumab apply to each treated eye and each injection. When treating bilaterally, physicians are reminded that adverse drug reactions can occur in each eye.

Physicians, other healthcare providers and patients are encouraged to report any observed or suspected adverse events according to local country requirements. You can make a report to Novartis at

Prescribing information and label updates

Label updates have been approved by several health authorities, including the FDA and the EMA to include characterization of the adverse events, retinal vasculitis (RV) and retinal vascular occlusion (RO), as part of the spectrum of IOI. RV and/or RO have been reported with the use of Beovu in patients with wet AMD. These events have typically occurred in the presence of IOI.

To request the prescribing information for your country, click here